Resultats de la cerca - Andrea Pirzkall

  • Mostrar 1 - 17 resultats de 17
Refinar resultats
  1. 1
    Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients

    Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients per Xiaojuan Li, Ying Lü, Andrea Pirzkall, Tracy R. McKnight, Sarah J. Nelson

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

    Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy per Suja Saraswathy, Forrest W. Crawford, Kathleen R. Lamborn, Andrea Pirzkall, Susan M. Chang, Soonmee Cha, Sarah J. Nelson

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformal Radiation Therapy With Respect to Pre–Radiation Therapy Magnetic Resonance Spectroscopic Findings

    Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformal Radiation Therapy With Respect to Pre–Radiation Therapy Magnetic Resona... per Ilwoo Park, Gregory Tamai, Michael Lee, Cynthia Chuang, Susan M. Chang, Mitchel S. Berger, Sarah J. Nelson, Andrea Pirzkall

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume

    Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volu... per Joonmi Oh, Roland G. Henry, Andrea Pirzkall, Ying Lü, Xiaojuan Li, I. Catalaa, Susan M. Chang, William P. Dillon, Sarah J. Nelson

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM

    Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM per Forrest W. Crawford, Inas S. Khayal, Colleen McGue, Suja Saraswathy, Andrea Pirzkall, Soonmee Cha, Kathleen R. Lamborn, Susan M. Chang, Mitchel S. Berger, Sarah J. Nelson

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

    Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma per Andrea Pirzkall, Colleen McGue, Suja Saraswathy, Soonmee Cha, Raymond Liu, Scott R. VandenBerg, Kathleen R. Lamborn, Mitchel S. Berger, Susan M. Chang, Sarah J. Nelson

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Molecular Biomarker Analyses Using Circulating Tumor Cells

    Molecular Biomarker Analyses Using Circulating Tumor Cells per Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, Heidi Savage, Ajay Pandita, Ru‐Fang Yeh, Andrea Pirzkall, Bernard M. Fine, Lukas C. Amler, Daniel S. Chen, Mark R. Lackner

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib per Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

    Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Er... per Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the... per Antonio Jimeno, Jean‐Pascal Machiels, Lori J. Wirth, Pol Specenier, Tanguy Y. Seiwert, F. Mardjuadi, Xiaodong Wang, Amy V. Kapp, S. Royer-Joo, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Paul Clement

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors per Dejan Juric, Rodrigo Dienstmann, Andrés Cervantes, Manuel Hidalgo, Wells A. Messersmith, George R. Blumenschein, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

    High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck per David S. Shames, Juliet G. Carbon, Walter Kim, Adrian M. Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard M. Stern, Jeff Settleman, Timothy R. Wilson, Garret M. Hampton, Robert L. Yauch, Andrea Pirzkall, Lukas C. Amler

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

    Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter per Xueping Qu, Thomas Sandmann, Henry F. Frierson, Lingfeng Fu, Eloisa Fuentes, Kimberly Walter, Kwame Okrah, Craig A. Rumpel, Christopher A. Moskaluk, Shi‐Long Lu, Yulei Wang, Richard Bourgon, Elicia Penuel, Andrea Pirzkall, Lukas C. Amler, Mark R. Lackner, Josep Tabernero, Garret M. Hampton, Omar Kabbarah

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

    Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) per Jérôme Fayette, Lori J. Wirth, Cristina Oprean, Anghel Adrian Udrea, Antonio Jimeno, Danny Rischin, Christopher M. Nutting, Paul M. Harari, Tibor Csőszi, Dana Cernea, Paul E. O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan B. Vermorken

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Canc... per Andrew G. Hill, Michael Findlay, Matthew Burge, Christopher Jackson, Pilar Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffery, Maria Di Bartolomeo, John Bridgewater, Andrew L. Coveler, Manuel Hidalgo, Amy V. Kapp, Roxana I. Sufan, Bruce McCall, William D. Hanley, Elicia Penuel, Andrea Pirzkall, Josep Tabernero

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors per Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles J. Link, Ray Lin, Stephanie Royer‐Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors per Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: